Bio-Hybrid Material, Production Method Therefor, and Stent
    11.
    发明申请
    Bio-Hybrid Material, Production Method Therefor, and Stent 有权
    生物混合材料,其生产方法和支架

    公开(公告)号:US20130245240A1

    公开(公告)日:2013-09-19

    申请号:US13989279

    申请日:2011-11-24

    Abstract: Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material (101) used includes an alloy part (11) free of Ni, an organic acid (12) having two or more active esters, and a cytokine (13). The alloy part (11) free of Ni forms an ester bond with the organic acid (12), and the organic acid (12) and the cytokine (13) are immobilized via an amide bond.

    Abstract translation: 提供了不引起镍离子洗脱并具有优异的内皮化能力的生物混合材料,其制备方法和支架。 使用的生物混合材料(101)包括不含Ni的合金部分(11),具有两种以上活性酯的有机酸(12)和细胞因子(13)。 不含Ni的合金部分(11)与有机酸(12)形成酯键,有机酸(12)和细胞因子(13)通过酰胺键固定。

    Biological low-molecular-weight derivatives
    14.
    发明授权
    Biological low-molecular-weight derivatives 失效
    生物低分子量衍生物

    公开(公告)号:US07741454B2

    公开(公告)日:2010-06-22

    申请号:US10527694

    申请日:2003-09-11

    CPC classification number: C07D207/02 C07D207/46

    Abstract: The crosslinking agents and condensing agents that have been employed in biological adhesives and in treating medical devices such as cardiac valves are non-natural compounds synthesized artificially. Thus, they are not metabolized in vivo and exhibit toxicity to living bodies. These compounds are thus used only in a restricted amount and for limited purposes in the clinical sites. The present invention provides a biological low-molecular-weight derivative obtained by modifying carboxyl groups of a biological low-molecular-weight compound with N-hydroxysuccinimide, N-hydroxysulfosuccinimide, or a derivative thereof and a crosslinked high-molecular-weight product obtained by crosslinking various high-molecular-weight compounds with this derivative.

    Abstract translation: 已经用于生物粘合剂和治疗医疗装置如心脏瓣膜的交联剂和缩合剂是人工合成的非天然化合物。 因此,它们不会在体内代谢并对活体表现出毒性。 因此,这些化合物仅在临床部位中仅限于有限的目的和用途。 本发明提供一种通过用N-羟基琥珀酰亚胺,N-羟基磺基琥珀酰亚胺或其衍生物修饰生物低分子量化合物的羧基得到的生物学低分子量衍生物和通过以下方法得到的交联的高分子量产物: 用该衍生物交联各种高分子量化合物。

    Biodegradable and pressure-sensitive material for medical use
    15.
    发明申请
    Biodegradable and pressure-sensitive material for medical use 审中-公开
    用于医疗用途的可生物降解和压敏材料

    公开(公告)号:US20060239958A1

    公开(公告)日:2006-10-26

    申请号:US10543156

    申请日:2004-02-05

    CPC classification number: A61L24/043 A61L24/0042 A61L2430/36

    Abstract: Disclosed is a two-component, bio-degradable/absorbable adhesive medical material, which has a bonding component comprising a biodegradable polymer, and a hardening component comprising a low-molecular-weight derivative prepared by modifying a carboxyl group in a di- or tri-carboxylic acid of the citric acid cycle, with an electron-attracting group (one or a combination of two or more selected from the group consisting of a succinimidyl group, a sulfosuccinimidyl group, a maleimidyl group, a phthalimidyl group, an imidazolyl group, a nitrophenyl group and a tresyl group, and derivatives thereof). The present invention is intended to meet the need for developing a biological tissue adhesive having strong bonding force and low biological toxicity, in the situation where a conventional hemostatic material, blood-vessel embolizing material, sealant or aneurysm closing material has been liable to peel off from its applied site and has not been able to achieve sufficient hemostatic effect or sealing/closing strength in occluding a blood vessel, stopping bleeding, sealing air-leak or closing an aneurysm.

    Abstract translation: 公开了一种双组分生物可降解/可吸收的粘合剂医疗材料,其具有包含可生物降解的聚合物的粘合组分和包含通过改性二 - 或三(C)中的羧基制备的低分子量衍生物的硬化组分 - 具有吸电子基团(一种或两种或更多种选自琥珀酰亚胺基,磺基琥珀酰亚胺基,马来酰亚胺基,苯二酰亚胺基,咪唑基,咪唑基, 硝基苯基和甲酚基,及其衍生物)。 本发明旨在满足在常规止血材料,血管栓塞材料,密封剂或动脉瘤闭合材料易于剥离的情况下开发具有强结合力和低生物毒性的生物组织粘合剂的需要 从其应用场所,并且在闭塞血管,停止出血,密封空气泄漏或闭合动脉瘤方面未能达到充分的止血效果或密封/闭合强度。

    Scaffold material for regeneration of hard tissue/soft tissue interface
    16.
    发明申请
    Scaffold material for regeneration of hard tissue/soft tissue interface 失效
    支架材料用于再生硬组织/软组织界面

    公开(公告)号:US20060165663A1

    公开(公告)日:2006-07-27

    申请号:US10516818

    申请日:2003-05-02

    CPC classification number: A61L27/3839 A61L27/46 C08L5/00

    Abstract: This invention relates to a scaffold consisting of a biodegradable polymeric material with a composition gradient of calcium phosphate that is capable of effectively regenerating the hard/soft tissue interface and an implant for hard/soft tissue filling with the utilization of such scaffold.

    Abstract translation: 本发明涉及由能够有效地再生硬/软组织界面的具有磷酸钙组成梯度的可生物降解的聚合物材料和用于硬/软组织填充以利用这种支架的植入物构成的支架。

    Bio-hybrid material, production method therefor, and stent
    18.
    发明授权
    Bio-hybrid material, production method therefor, and stent 有权
    生物混合材料,其生产方法和支架

    公开(公告)号:US09428588B2

    公开(公告)日:2016-08-30

    申请号:US13989279

    申请日:2011-11-24

    Abstract: Provided is a bio-hybrid material that does not cause elution of nickel ions and has an excellent endothelialization ability, a production method therefor, and a stent. The bio-hybrid material (101) used includes an alloy part (11) free of Ni, an organic acid (12) having two or more active esters, and a cytokine (13). The alloy part (11) free of Ni forms an ester bond with the organic acid (12), and the organic acid (12) and the cytokine (13) are immobilized via an amide bond.

    Abstract translation: 提供了不引起镍离子洗脱并具有优异的内皮化能力的生物混合材料,其制备方法和支架。 使用的生物混合材料(101)包括不含Ni的合金部分(11),具有两种以上活性酯的有机酸(12)和细胞因子(13)。 不含Ni的合金部分(11)与有机酸(12)形成酯键,有机酸(12)和细胞因子(13)通过酰胺键固定。

    Medical Material and Process for Producing the Same
    19.
    发明申请
    Medical Material and Process for Producing the Same 审中-公开
    医疗材料及其生产工艺

    公开(公告)号:US20070254013A1

    公开(公告)日:2007-11-01

    申请号:US10588309

    申请日:2005-02-01

    Abstract: [Object] A medical material that improves therapeutic effects in epithelial cells such as keratoconjunctival epithelial cells with the use of an amnion, and a process for producing the same are provided. [Solving Means] A medical material includes an amnion, which is a placental tissue, a polymer film bonded to one surface of the amnion and crosslinked, and cells adhered to the other surface of the amnion. A process for producing the medical material includes the steps of preparing an amnion from which the spongy layer is removed, bonding a biocompatible polymer film to one surface of the amnion followed by crosslinking, adhering epithelial stem cells to the other surface of the amnion, and proliferating epithelial cells from the epithelial stem cells on the surface of the amnion.

    Abstract translation: 提供了一种使用羊膜改善上皮细胞如角膜结膜上皮细胞治疗效果的医疗材料及其制造方法。 [解决方案]药物材料包括羊膜,羊膜组织,与羊膜的一个表面结合并交联的聚合物膜,以及附着在羊膜的另一表面的细胞。 制造医疗材料的方法包括以下步骤:制备从其中除去海绵层的羊膜,将生物相容性聚合物膜粘合到羊膜的一个表面,然后交联,将上皮干细胞粘附到羊膜的另一个表面,以及 从羊膜表面的上皮干细胞增殖上皮细胞。

    Hydroxyapatite, composite, processes for producing these, and use of these
    20.
    发明授权
    Hydroxyapatite, composite, processes for producing these, and use of these 失效
    羟基磷灰石,复合材料,制造方法及其应用

    公开(公告)号:US06395037B1

    公开(公告)日:2002-05-28

    申请号:US09462220

    申请日:2000-01-03

    CPC classification number: A61L27/12 C01B25/32

    Abstract: A hydroxyapatite consisting substantially of Ca10(PO4)6(OH)2, and having a crystal structure which has at least two diffraction peaks at 31-32 degrees and 26 degrees in X-ray diffractometry; and a process for producing a hydroxyapatite which comprises the step (A) of immersing a substrate in a first aqueous solution containing calcium ions and a second solution containing PO4 ions to generate the hydroxyapatite at least on the surface of the substrate and the step (B) of recovering the hydroxyapatite from the substrate.

    Abstract translation: 基本上由Ca10(PO4)6(OH)2组成的具有晶体结构的羟基磷灰石,在X射线衍射中具有至少两个衍射峰,在31-32度和26度; 以及生产羟基磷灰石的方法,其包括将底物浸入含有钙离子的第一水溶液和含有PO 4离子的第二溶液以至少在基材的表面上产生羟基磷灰石的步骤(A)和步骤(B )从基底中回收羟基磷灰石。

Patent Agency Ranking